Targeting, Attacking, and Eradicating Cancers®
Collaboration with the National Cancer Institute for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors
Approval by the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancermay.
Collaboration with Regeneron Pharmaceuticals for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors
SillaJen is listed on KOSDAQ market in South Korea.Jan.
SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer.
SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products".
SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer.
SillaJen acquires Jennerex, Inc., the global leader in oncolytic immunotherapeutics.
Jennerex was an early leader in the oncolytic virus field.Jennerex researchers showed that Pexa-Vec acts in three distinct ways to attackcancer: by infecting and killing cancer cells, by cutting off the blood supply totumors, and by activating the body’s own immune system to fight cancer.
US FDA designated Pexa-Vec as an orphan drug.
Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer.
European Medicines Agency (EMA) designated Pexa-Vec as an orphan drug for Live Cancer.
Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007).
Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001).
SillaJen, Inc. was established.
Jennerex, Inc. (San Francisco, USA) was established.